Novotech in expansion mode as CRO sector continues to grow at 15%

BioPacificVentures and Co-Investor Capital Partners invest in Novotech and back expansion plans Sydney, Australia, Orange County, CA – October 21, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, is now in rapid expansion mode as the CRO sector fundamentals continue to strengthen with [...]

Novotech alerts Pharma and Biotechs at DIA 2007 to Australias new R&D tax break that applies to clinical trials

New Tax break comes into effect July 1, 2007 Atlanta, GA – July 1, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, announced on the eve of DIA 2007 that the new tax breaks for research in Australia, which includes clinical trials, starts [...]

Novotech says Australia ideally placed to become Bioequivalence trials hub

Sydney, Australia, May 15, 2007 — Novotech, the largest independent Australian owned contract research organization (CRO) with expertise in TGA/EMEA/FDA registration said today Australia should aggressively market its bioequivalence trials capabilities overseas and take a large share of the multi-billion dollar sector. Already more than 70% of Novotech’s bioequivalence work comes from offshore, according to [...]

Updated checklist for CRO partnering and trials selection in Australasian region announced at BIO 2007

May 8, 2007 – Boston, MA — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, has released its updated “Clinical Trials Checklist” for CROs, biotech, pharma and even VCs, to assist in the often challenging task of selecting a clinical trials partner in the Australasian [...]

Novotech recognized in Deloitte Technology Fast 500 Asia Pacific 2006 Program

Dec 12, 2006 – Sydney, Australia Novotech, the largest independent Australian owned contract research organization (CRO) and the only Australian CRO with offices in the USA, announced today that it is a winner in the Deloitte Fast 500 Asia Pacific 2006 Program. The Program run by the leading global consultancy, is supported by the Deloitte [...]

Novotech CRO opens second office in the USA

Oct 3, 2006 – Sydney, Australia — Novotech, the largest independent Australian owned contract research organization (CRO) announced today it has accelerated its US expansion plans with the opening of a second office in the USA specifically designed to service the maturing Australian biotech sector. Novotech CEO Alek Safarian said the new office in New [...]

Novotech presents checklist for CRO partnering and trials selection in Australia & Asia at DIA 2006

June 21, 2006 – Philadelphia, PA — Novotech, the largest Australian owned contract research organization (CRO) presented to the Drug Industry Association (DIA) annual conference 2006 this week, a check list for the selection of a CRO in Australia and the Asian region. At Novotech’s DIA press conference, Novotech CEO Alek Safarian said all eyes [...]

Novotech checklist for CRO partnering and trials selection is Australia & Asia

June 21, 2006 – Philadelphia, PA —Size match – ensure the CRO is a good match in organizational size and reach. Make sure the CRO has experience working with companies at a similar stage and growth phase, eg, small to medium sized biotechs often find it frustrating working with the large global CROs as they [...]

Novotech wins prestigious Asian CRO of The Year Award

June 20, 2006 – Philadelphia, PA — Novotech, the largest Australian owned contract research organization (CRO) announced today it has been recognized by Frost & Sullivan for its clinical research capabilities at the inaugural Asia Pacific Healthcare Best Practice Awards, winning The Asian CRO of the Year – Australia Award. According to Frost & Sullivan [...]

Novotech’s expansion to USA reaps multimillion

April 9, 2006 – Chigago, Il — Novotech, the largest Australian owned contract research organization (CRO) announced today at BIO 2006 in Chicago Il., an AUD4 million deal with US biotech firm SkyePharma (LSE: SKP; Nasdaq: SKYE) to conduct a key trial required for the US FDA. This is the first major deal for Novotech’s [...]

« Previous Page — Next Page »